Physician profile
Anna Schaefer
NPI 1336855949
$5,949.32
in general payments reported to CMS, 2019-2025
27 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $721 · 2024: $3,016 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,636 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,636.44 |
| Education | $312.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.47 | 2023-2025 | |
| Janssen Biotech, INC. | $836.60 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $441.08 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $388.70 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $345.35 | 2023-2025 | Sotyktu, Sprycel |
| Amgen INC. | $329.19 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $274.07 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $256.67 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $243.50 | 2023-2025 | Blu-U, Odomzo, Absorica Ld |
| Ucb, INC. | $241.47 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $201.60 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $173.36 | 2024-2025 | Cabtreo, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.81 | 2024-2025 | Spevigo |
| Almirall LLC | $125.42 | 2024-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $115.73 | 2024-2025 | Aklief, Nemluvio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $110.47 | 2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Dermavant Sciences, INC. | $63.60 | 2023-2024 | Vtama |
| Incyte Corporation | $61.64 | 2024 | Opzelura |
| Lnhc, INC | $46.66 | 2025 | Zelsuvmi |
| Convatec INC. | $40.36 | 2024 | |
| Biofrontera INC. | $34.59 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $33.28 | 2024 | |
| Organogenesis INC. | $22.90 | 2025 | Via Matrix |
| Organon LLC | $18.45 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $15.90 | 2024 | Ycanth |
| Genentech USA, INC. | $13.46 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.